Phase 3 Rheumatoid Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who gave their informed consent before any study activities began
- People who previously took part in one of the related Phase 3 Sjögren's syndrome studies (HZNP-DAZ-301 or HZNP-DAZ-303), received the study drug or placebo, and completed that study up to the Week 48 point
- People who are able to receive the first dose of this follow-on study within 28 days of their Week 48 visit in the previous study
Who may not be able to join:
- People who have a significant active infection on Day 1, including ongoing or long-term infections that need antibiotic or antiviral treatment, as assessed by the study doctor
- People who plan to take part in another clinical trial involving an investigational drug or procedure during this study
- People whose health changed or worsened during the earlier Phase 3 studies in a way that, in the opinion of the study doctor or sponsor, could affect safety assessments or change the risks of taking the study drug
- People who have planned surgeries or hospital stays that, in the opinion of the study doctor or sponsor, could interfere with safely monitoring and evaluating the study
- People who plan to receive a live or live-attenuated vaccine during this study
- Women who are able to become pregnant but are unwilling to use the contraception method specified in the study plan during treatment and for 12 weeks after the last dose
- Women who are pregnant, breastfeeding, or planning to become pregnant during the study
- People who have a known allergy or sensitivity to any of the study drug ingredients or related products
- People who are unlikely to be able to attend all required study visits or follow all required study procedures, to the best of the participant's and study doctor's knowledge
- People who have a history of, or currently have, any other significant health condition that, in the opinion of the study doctor or an Amgen physician, could pose a safety risk or affect how the study results are evaluated
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: MD, Amgen
Phone: 866-572-6436
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.